Telik, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer and inflammatory diseases. Its lead product candidate TELCYTA is a small molecule cancer drug product designed to be activated in cancer cells. TELCYTA is in phase 3 clinical trials for the treatment of platinum resistant or refractory ovarian cancer and lung cancer. The company’s other product TELINTRA is a small molecule bone marrow stimulant that activates signaling pathways and lead to the growth and differentiation of blood cells. TELINTRA is in Phase-2 trials in patients with myelodysplastic syndrome, a preleukemic...